Abstract and Introduction
Against the backdrop of an increasing opioid use epidemic and a marked acceleration of prescription opioid–related deaths,[1,2] there has been an impetus to explore the usefulness of alternative and co-analgesic agents to assist patients with chronic pain. Preclinical studies employing animal-based models of human pain syndromes have demonstrated that cannabis and chemicals derived from cannabis extracts may mitigate several pain conditions.
Because there are significant comorbidities between psychiatric disorders and chronic pain, psychiatrists are likely to care for patients with chronic pain. As the availability of and interest in cannabinoid-based medications (CBM) increases, psychiatrists will need to be apprised of the utility, adverse effects, and potential drug interactions of these agents.
Curr Psychiatr. 2021;20(5):21-33. © 2021 Current Psychiatry